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ABSTRACT Biosynthetic gene clusters (BGCs) are organized groups of genes in-
volved in the production of specialized metabolites. Typically, one BGC is responsi-
ble for the production of one or several similar compounds with bioactivities that
usually only vary in terms of strength and/or specificity. Here we show that the pre-
viously described ferroverdins and bagremycins, which are families of metabolites
with different bioactivities, are produced from the same BGC, whereby the fate of
the biosynthetic pathway depends on iron availability. Under conditions of iron de-
pletion, the monomeric bagremycins are formed, representing amino-aromatic anti-
biotics resulting from the condensation of 3-amino-4-hydroxybenzoic acid with p-
vinylphenol. Conversely, when iron is abundantly available, the biosynthetic pathway
additionally produces a molecule based on p-vinylphenyl-3-nitroso-4-hydroxy-
benzoate, which complexes iron to form the trimeric ferroverdins that have anticho-
lesterol activity. Thus, our work shows a unique exception to the concept that BGCs
should only produce a single family of molecules with one type of bioactivity and
that in fact different bioactive molecules may be produced depending on the envi-
ronmental conditions.
IMPORTANCE Access to whole-genome sequences has exposed the general inci-
dence of the so-called cryptic biosynthetic gene clusters (BGCs), thereby renewing
their interest for natural product discovery. As a consequence, genome mining is the
often first approach implemented to assess the potential of a microorganism for
producing novel bioactive metabolites. By revealing a new level of complexity of
natural product biosynthesis, we further illustrate the difficulty of estimation of the
panel of molecules associated with a BGC based on genomic information alone. In-
deed, we found that the same gene cluster is responsible for the production of
compounds which differ in terms of structure and bioactivity. The production of
these different compounds responds to different environmental triggers, which sug-
gests that multiplication of culture conditions is essential for revealing the entire
panel of molecules made by a single BGC.
KEYWORDS Streptomyces, genome analysis, iron regulation, natural antimicrobial
products, secondary metabolism
Specialized metabolites are natural products (NPs) that play essential roles byhelping the producing strain to cope with various stresses, are used as weapons to
outcompete neighboring commensals, or are required at particular physiological or
developmental stages (1, 2). Besides their role in improving the fitness of microorgan-
isms in their habitat, among others, molecules emanating from the so-called secondary
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metabolism are of foremost therapeutic and agroindustrial importance (3, 4). These
bioactive compounds are produced by a form of machinery encoded by a group of
genes—a biosynthetic gene cluster (BGC)—that, in addition to biosynthetic genes,
typically includes genes for expression control, self-resistance, and export (4–6).
Genome sequencing of secondary-metabolite-producing microorganisms has re-
vealed an enormous potential to increase the known chemical space (5), with the
promise of new leads in human therapies or for sustainable agriculture. One of the
drivers of the renewed interest in NPs was the discovery of so-called cryptic BGCs that
are silent under routine laboratory conditions and may therefore specify molecules that
had so far been missed during pharmaceutical screening (7–9). An approach that is
rapidly gaining momentum is that of expressing cryptic BGCs in a heterologous chassis
strain or superhost and exchanging promoter elements within the BGC with those that
are expected to result in high levels of expression under laboratory conditions. How-
ever, there are several problems associated with this approach. First, it is still difficult to
effectively apply it through high-throughput strategies, and it is hard to establish the
promise of the activity of a certain BGC on the basis of the DNA sequence alone (10).
Second, examples of NPs that are produced from multiple BGCs, or by strains in
coculture, are accumulating (11, 12). Alternatively, a single BGC may also be responsible
for the production of many (up to over 100) structurally related molecules that differ in
terms of their activity (13–15), or BGCs can be associated into “superclusters” that
function to produce two or more similar molecules (16, 17). Thus, to optimally exploit
the chemical space of NPs, we need to understand the connection between the
genomic diversity and the chemical diversity of their biosynthetic pathways.
Here we provide an example that further illustrates the complexity of analyses
designed to estimate the metabolome profile as well as the industrial potential of a
microorganism based on the genomic information alone. Our work revealed that the
ferrous compounds called ferroverdins (Fig. 1, structures 1 to 3 [18–20]), which are
inhibitors of cholesterylester transfer protein (CETP) and thus are molecules potentially
able to reduce the risk of atherosclerosis (21), and the antibiotics called bagremycins
(Fig. 1, structures 4 to 9 [22–24]) are synthesized from the same BGC. These molecules
not only have completely different biological functions, but their biosynthesis also
requires different environmental triggers. These findings challenge the concept that a
FIG 1 Structures of ferroverdins and bagremycins produced by S. lunaelactis strains. The top line displays the structures of ferroverdins
(structures 1 to 3) and the bottom line the structures of bagremycins (structures 4 to 9), including the molecular formula of each. The
monomer specific to ferroverdin B (hydroxy-p-vinylphenyl-3,4-NHBA) and the monomer specific to ferroverdin C (and carboxy-p-
vinylphenyl-3,4-NHBA) are shaded in gray.
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given BGC is associated with production of similar compounds in terms of building
blocks, structure, bioactivity, and conditions for production.
RESULTS
Streptomyces lunaelactis produces ferroverdins and bagremycins. Strains of
Streptomyces lunaelactis, including type strain MM109T, were previously isolated from
cave moonmilk deposits (25–27). Strain MM109T produces a green pigment whose
presence was attributed to the biosynthesis of ferroverdin A (25), a homotrimer of
p-vinylphenyl-3-nitroso-4-hydroxybenzoate (p-vinylphenyl-3,4-NHBA) complexed with
one ferrous ion (18, 19). To assess the metabolomic response of S. lunaelactis, including
the conditions under which ferroverdin A is produced, strain MM109T was grown under
different culture conditions. For this assessment, disc diffusion assays were performed
in the presence of a range of different metals.
The results revealed that only the addition of the ferric iron salt FeCl3 (as well as the
addition of ferrous iron FeSO4; data not shown) triggered production of the green
pigmented ferroverdin A by S. lunaelactis MM109T (Fig. 2A). Production of ferroverdin
A (structure 1 in Fig. 1; see also Fig. 2C) was triggered at a FeCl3 concentration as low
as 0.01 mM (Fig. 2B). Ultraperformance liquid chromatography-tandem mass spectrom-
etry (UPLC-MS/MS) analysis of extracts of strain MM109T identified an ion peak of m/z
876.11 [M-], corresponding to ferroverdin B (structure 2 in Fig. 1), and a distinct ion peak
of m/z 904.11 [M-] corresponding to ferroverdin C (structure 3 in Fig. 1). Ferroverdin B
and ferroverdin C heterotrimers differ from ferroverdin A in only one of the three
ligands used to complex ferrous iron, namely, hydroxy-p-vinylphenyl-3,4-NHBA for
ferroverdin B and carboxy-p-vinylphenyl-3,4-NHBA for ferroverdin C (Fig. 1).
FIG 2 Production of ferroverdins by S. lunaelactis MM109T. (A) Paper disc diffusion assays with various metal salts (1 mM). Note that FeCl3 was the only metal
salt able to trigger the green pigmentation of the mycelium of S. lunaelactis MM109T grown on R2YE agar plates. (B) Induction of ferroverdin production by
iron. (Top panels) Phenotypes. (Bottom left panel) HPLC profiles of the crude metabolite extracts. The HPLC profile analyses were performed with crude
acetonitrile extracts of S. lunaelactis MM109T grown on R2YE agar plates (black line) or on R2YE medium supplied with 1 mM FeCl3 (green line). (Bottom right
panel) Semiquantitative analysis of ferroverdin production (Ferroverdin A prod.) by S. lunaelactis MM109T grown on R2YE agar plates supplied with various
concentrations of FeCl3. The areas of the integrated HPLC peaks of ferroverdin A (observed at 440 nm) were normalized, and the value measured in R2YE plus
0.5 mM FeCl3 was fixed at 100%. Bars represent means of results from biological triplicates. AU, arbitrary units. (C) Extracted ion chromatograms (EIC) of the
three ferroverdins detected in the full extract of S. lunaelactis MM109T. RA, relative abundance.
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Under culture conditions allowing the production of ferroverdins, the crude extract
of S. lunaelactis MM109T displayed antibacterial activity against Gram-positive bacteria,
as exemplified by the observed growth inhibition against the test strain Staphylococcus
aureus (Fig. 3A). As pure ferroverdins do not possess antibacterial activities against S.
aureus (Fig. 2C, left panel), we undertook the extraction, purification, and identification
of the antibacterial metabolites produced by S. lunaelactis. High-pressure liquid chro-
matography (HPLC) fractionation and subsequent analysis of the active fractions by
UPLC-MS/MS identified molecular ion species corresponding to bagremycin A (m/z
254.0824 [M-H]-), bagremycin B (m/z 296.0931 [M-H]-), bagremycin C (m/z 415.0974
[M-H]-), bagremycin E (m/z 239.0714 [M-H]-), bagremycin F (m/z 429.1133 [M-H]-), and
bagremycin G (m/z 282.0777 [M-H]-) (Fig. 3B and C; see also structures 4 to 9 in Fig. 1).
Bagremycins are amino-aromatic antibiotics resulting from the condensation of
3-amino-4-hydroxybenzoic acid (3,4-AHBA) with p-vinylphenol (22–24).
MM109T is the type strain of S. lunaelactis, but many other strains belonging to the
species S. lunaelactis were isolated from different moonmilk deposits. Multilocus se-
quence analysis (MLSA) performed on 15 independently isolated S. lunaelactis strains
grouped them into different clusters (Fig. 4A), and one representative of each cluster
was investigated for the production of bagremycins and ferroverdins. The crude
extracts of the selected eight different representative strains (MM25, MM31, MM37,
MM40, MM83, MM91, MM109, and MM113) were analyzed by HPLC, which revealed
that all strains except strain MM91 were able to produce at least one bagremycin and
one ferroverdin (Fig. 4B). These data suggest that the production of bagremycins, like
the production of ferroverdins, is a common feature of moonmilk-dwelling strains
belonging to the species S. lunaelactis.
Identification of a BGC similar to fev and bag clusters in S. lunaelactis MM109T.
In order to identify the genes involved in the production of bagremycins (bag) and/or
ferroverdins (fev) in S. lunaelactis MM109T, the genome of this strain (28) was mined
using antiSMASH v4.0 software (29). A total of 37 BGCs were identified, specifically, 36
BGCs on the linear chromosome and 1 additional BGC on linear plasmid pSLUN1 (see
FIG 3 Production of bagremycins by S. lunaelactis MM109T. (A) Phenotype of S. lunaelactis MM109T grown on agar plates with R2YE plus 1 mM FeCl3 and paper
disc diffusion assay assessing the antibacterial activity of the full acetonitrile extract (including both intracellular and extracellular extracts). (B) HPLC-separated
fractions of the crude metabolite extract of S. lunaelactis MM109T (RA, relative abundance). Note the paper disc diffusion assay details revealing the antibacterial
activity associated with pure bagremycin A (peak 4), and bagremycin B (peak 5); ctrl-, paper disc infused with acetonitrile used as negative control (no
antibacterial activity). (C) Extracted ion chromatograms (EIC) of the six known bagremycins detected in the full extract of S. lunaelactis MM109T.
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Fig. S1 in the supplemental material). BGC 12 (from S. lunaelactis 21350 [SLUN_21350]
to SLUN_21430 [28]) exhibits strong gene synteny with the bagremycin BGC from
Streptomyces sp. Tü 4128 (30, 31), with high similarity between the predicted gene
products (coverage, 99%; average identity, 86.2%; average similarity, 91.9%) (Fig. 5A)
(Table 1). Surprisingly, BGC 12 displayed similarly strong gene synteny and high
similarity between its gene products and those seen with the fev cluster (GenBank
accession no. AB689797) of the ferroverdin producer Streptomyces sp. WK-5344 (cov-
erage, 99%; average identity, 85.8%; average similarity, 91.3%) (Fig. 5A) (Table 1). The
levels of identity between the proposed fev cluster of Streptomyces sp. WK-5344 and the
bag cluster of Streptomyces sp. Tü 4128 were even greater, with (on average) 96%
amino acid (aa) identity and 97.4% similarity (Fig. 5A) (Table 1). The exceptionally high
levels of average amino acid identity suggest that biosynthesis of bagremycins and
biosynthesis of ferroverdins might be mediated by the same BGC. This conjecture was
further supported by the results of comparative analysis of the BGCs involved in the
production of other amino/nitroso-aromatic metabolites, i.e., the nsp gene cluster for
biosynthesis of 4-hydroxy-3-nitrosobenzamide in Streptomyces murayamaensis (32) and
the gri gene cluster involved in grixazone production in Streptomyces griseus (33). The
nsp and gri clusters share seven homologous genes with those identified in the bag/fev
cluster (Fig. 5A) (Table 1), specifically, those encoding (i) the Streptomyces antibiotic
regulatory protein (SARP)-family transcriptional activators (BagI, FevR, NspR, and GriR),
(ii) the LuxR-family transcription regulators (BagY, FevT, NspT, and GriT), (iii) the
3,4-AHBA synthases (BagC, FevH, NspH, and GriH), (iv) the DhnA-type aldolase (BagB,
FevI, NspI, and GriI), (v) the o-aminophenol oxidases (BagH, FevF, NspF, and GriF), (vi)
the copper chaperones (BagZ, FevE, NspE, and GriE), and (vii) the flavin adenine
dinucleotide (FAD)-dependent oxygenases (BagK/G. FavA1/A2, NspA, and GriA). Phy-
logeny analyses revealed that Fev and Bag proteins always branched together in
clusters separated from Nsp and Gri proteins (Fig. 5B).
Finally, only one single BGC is similar to the fev and bag gene clusters in S. lunaelactis
MM109T as well as in the genomes of 16 other S. lunaelactis strains. This makes it
extremely unlikely that bagremycins and ferroverdins should be specified by two
different BGCs. A plausible pathway for the synthesis of both bagremycins and fer-
roverdin A from the fev/bag cluster is proposed in the Discussion (see also Fig. 8).
FIG 4 Production of ferroverdins and bagremycins by different S. lunaelactis strains. (A) Multilocus sequence analysis (MLSA) of moonmilk
isolates belonging to the species S. lunaelactis. (B) HPLC profiles at the indicated retention times were determined for monitoring
bagremycin and ferroverdin production by eight different S. lunaelactis strains grown on ISP7 medium.
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Inactivation and/or duplication of fevR affects both ferroverdin and bagremy-
cin production. Among the S. lunaelactis strains that were collected from the moon-
milk samples, strain S. lunaelactis MM91, which does possess a complete fev/bag cluster
(GenBank accession no. MG708299), failed to produce the ferroverdin-associated green
pigmentation under conditions of growth in iron-containing media (Fig. 6A and B).
MM91 also showed reduced production of all bagremycins except bagremycin B
(Fig. 6C). The phenotype of S. lunaelactis MM91 allowed a forward genetic approach to
FIG 5 Comparative analysis of known BGCs involved in the production of nitroso-aromatic and amino-aromatic metabolites in Streptomyces spp.
(A) Genetic organization of the BGCs involved in ferroverdin (fev), bagremycin (bag), 4-hydroxy-3-nitrosobenzamide (nsp), and grixazone (gri)
production in Streptomyces spp. See Table 1 for the known function and/or predicted function associated with the product of each gene. (B)
Phylogeny analysis of proteins conserved among the ferroverdin (fev), bagremycin (bag), 4-hydroxy-3-nitrosobenzamide (nsp), and grixazone (gri)
BGCs. The trees were rooted by including as outgroup the proteins most similar to S. lunaelactis MM109T proteins.
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21345 Aminotransferase NA 23415 (NS);
WP_122618577
NF NF
21350 ORF1 Prephenate dehydrogenase 89–93;
BAM73624
Pseudo-23410 NF NF


























































21390 fevE Copper chaperon 73–79;
BAM73632

































































NS; BAM73641 Pseudo-23325 NF NF
abag, bagremycin cluster (NZ_QTSY01000069) (DXM28_RS); fev, ferroverdin cluster (AB689797); gri, grixazone cluster (AB259663); nsp, nitrosobenzamide cluster
(AB530136). Abbreviations: ID, identifier; sim, similarity; NA, sequence not available; NS, not similar; NF, none found.
bGene names were provided based on the fev cluster of Streptomyces WK-5344 (GenBank accession no. AB689797.1). Paired numbers refer to the percentage of amino
acid identity and similarity, respectively.
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assess if the fev cluster is indeed responsible for production of both bagremycins and
ferroverdins. Genome sequencing and single nucleotide polymorphism (SNP) analysis
of S. lunaelactis strain MM91 revealed a deletion at nucleotide (nt) position 337 of
SLUN_21380 (bagI or fevR), which encodes the likely pathway-specific activator of the
BGC (Fig. 6D). This deletion resulted in a frameshift leading to a premature stop codon,
17 amino acids downstream of the deletion, and thus in a truncated (and likely inactive)
protein.
To ascertain whether FevR/BagI is required for both ferroverdin and bagremycin
production, the SLUN_21380 gene was first interrupted in strain S. lunaelactis MM109T
by insertion of a thiostreptone resistance cassette. Introduction of plasmid pBDF028
into spores of MM109T allowed isolation of thiostreptone-resistant clones in which
occurred a single recombination event corresponding to a 791-bp internal fragment of
SLUN_21380 (fevR/bagI). The single-crossover event resulted in a duplication of fevR,
with the first copy lacking the last 86 nt, resulting in a truncated FevR protein, and the
second copy lacking the promoter region and the first 116 nt. One clone (referred to as
strain fevR here, where “” represents inactivation by interruption) was selected for
further analyses. Strain fevR displayed loss of the ferroverdin-associated green pig-
mentation under conditions of growth on iron-supplemented R2YE medium. HPLC
analysis of the crude extracts of strain fevR confirmed the absence of ferroverdins and
FIG 6 FevR (BagI) is involved in the production of both ferroverdin A and bagremycins. (A) Phenotypes of S. lunaelactis strains MM109T and MM91 grown in
media activating (R2YE plus FeCl3) or not inducing (R2YE) the production of ferroverdin A. (B) Semiquantitative analysis (HPLC) of ferroverdin A produced by
these strains. (C) Semiquantitative analysis (HPLC) of bagremycins produced by S. lunaelactis strains MM109T and MM91. (D) Identification in the fev cluster of
S. lunaelactis strain MM91 (accession number MG708299) of the in-frame deletion at nt position 337 of fevR encoding the SARP-family transcription activator.
(E) Details of HPLC profiles focused on peaks associated with bagremycin A, bagremycin B, bagremycin F, and ferroverdins from extracts of mutant strains of
S. lunaelactis MM109T in which fevR is inactivated (fevR) or with one supplementary copy of fevR (fevR). Abs, absorbance. WT, wild type.
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bagremycins (Fig. 6E). These data suggest that FevR/BagI is indeed the pathway-specific
activator for the BGC, and this interpretation was further supported by the observation
that introduction of an additional copy of fevR/bagI into S. lunaelactis MM109T resulted
in increased production of both ferroverdins and bagremycins (Fig. 6E). Finally, com-
plementation of fevR (strain MM109BD3; Table 2) by the low-copy-number plasmid
harboring an intact copy of fevR with its own promoter allowed restoration of produc-
tion of both ferroverdin and bagremycin (not shown).
Iron is required for production of p-vinylphenyl-3,4-NHBA but its presence not
mandatory for bagremycin biosynthesis. If ferroverdins are detected only when iron
is supplied in the cultivation media, a key issue that remains unaddressed is whether
iron is required only for complexation of the p-vinylphenyl-3,4-NHBA monomers
(and/or the other monomers required for ferroverdin B and C) or whether iron is
necessary for the synthesis of p-vinylphenyl-3,4-NHBA, the monomer of ferroverdins. An
HPLC chromatogram of extracts of S. lunaelactis MM109T grown on R2YE and R2YE






pJET1.2/blunt E. coli plasmid used for high-efficiency blunt-end cloning of PCR products (Ampr) Thermo Scientific
pBDF019 pJET1.2 derivative containing the slun21380 gene (fevR) and its upstream (217-bp) and
downstream (360-bp) regions (Ampr)
This study
pSET152 Integrative vector transmissible by conjugation from E. coli to Streptomyces spp. [lacZ,
ori (pUC18), aac(3)IV (Aprar), oriT (RK2), attP (ØC31), int (ØC31)]
42
pBDF021 pSET152 derivative containing the insertion of pBDF019 cloned in EcoRI and XbaI sites (Aprar) This study
pBDF027 pJET1.2 derivative containing an internal fragment (791 bp amplified with fevR118f_XbaI
and fevR909r_PstI primers) of the slun21380 (fevR) coding sequence (Ampr)
This study
pSET151 Nonreplicating plasmid in Streptomyces spp. [lacZ, oriT (RK2), xylE, tsr (Thior), bla (Ampr),
ori (pUC19)]
42, 43
pBDF028 pSET151 derivative containing the insertion of pBDF027 cloned in XbaI and PstI sites
(Ampr, Thior)
This study
pUZ8002 Nontransmissible plasmid supplying transfer functions for mobilization of oriT-containing
vectors from E. coli to Streptomyces spp. (Kanr)
41
pAU3-45 pSET152 derivative with a thiostrepton resistance gene inserted into the blunted NheI
restriction site [lacZ, ori (pUC18), aac(3)IV (Aprar), oriT (RK2), attP (ØC31), int (ØC31),
tsr (Thior)]
44
pBDF029 pBDF022 derivative containing the apramycin resistance cassette from pIJ773 cloned in
PstI and HindIII sites (Thior, Ampr, Aprar)
This study
pIJ773 pBluescript II SK()-based plasmid containing the apramycin resistance cassette [oriT (RK2)
 aac(3)IV (Aprar)] flanked by FRT (FLP recognition target) recombination sites
43
pBDF022 pHJL401 derivative containing the insert of pBDF019 cloned in EcoRI and XbaI sites
(Thior, Ampr)
This study
pHJL401 Intermediate-copy-number (10 copies) vector in Streptomyces spp. [lacZ, ori (pUC19),
ori (SCP2), tsr (Thior), bla (Ampr)]
42
Strains
E. coli DH5 General cloning host Gibco-BRL
E. coli ET12567 Nonmethylating (dam, dcm, hsdS null mutants) host for transfer of plasmid DNA into




Wild-type and reference strain of Streptomyces lunaelactis 25
Streptomyces lunaelactis
MM91
Wild-type strain Streptomyces lunaelactis MM91 26
Streptomyces lunaelactis
MM109BD1 (fevR)
MM109 derivative with pBDF028 inserted to disrupt gene slun21380 (fevR) (Thior) This study
Streptomyces lunaelactis
MM109BD2 (fevR)
MM109T derivative with pBDF021 inserted to add an additional copy of slun21380




Complementation of strain MM109BD1 (fevR) with pBDF029 (Thior, Aprar) This study
aAmpr, ampicillin resistance; lacZ, LacZ galactosidase alpha subunit coding sequence; ori (pUC18/pUC19), origin of replication of the pUC18/pUC19 plasmid (E. coli);
aac(3)IV, apramycin resistance marker; Aprar, apramycin resistance; oriT (RK2), origin of conjugative transfer from plasmid RK2; attP (ØC31), phage attachment site of
the ØC31 integrase [ int (ØC31)]; xylE, catechol 2,3-dioxygenase (reporter gene); tsr, thiostrepton resistance gene; Thior, thiostrepton resistance; bla, ampicillin
resistance gene; dam, dcm, hsdS, genotype of methylase-deficient E. coli strain; Cmlr, chloramphenicol resistance; Tetr, tetracycline resistance.
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supplied with 1 mM FeCl3 revealed the presence of the p-vinylphenyl-3,4-NHBA mono-
mer only when strain MM109T was grown under conditions of high levels of iron
(Fig. 7A). HPLC fractionation and subsequent UPLC-MS/MS analysis confirmed the
presence of a molecular ion species that corresponded to p-vinylphenyl-3,4-NHBA (m/z
268.06 [M-]) (Fig. 7B and C). Instead, bagremycins were detected under both sets of
conditions (Fig. S2), suggesting that, in contrast to the results seen with p-vinylphenyl-
3,4-NHBA, iron overload is not mandatory for their biosynthesis. Thus, iron is not only
required for complexation of the three p-vinylphenyl-3,4-NHBA ligands with ferrous ion
and for generation of ferroverdin A but is also necessary for their biosynthesis.
DISCUSSION
In this work, we provide genomic, genetic, and metabolomic evidence that a single
BGC (fev/bag) is responsible for the synthesis of both ferroverdins and bagremycins.
That a single BGC is responsible for the production of several related compounds is not
unusual, but several features make the case of the fev/bag BGC unique. For example,
the chemical compositions of ferroverdins and bagremycins (nitroso-aromatic versus
amino-aromatic compounds) are different, as are their structural organizations (trimers
versus monomers), whereas these two characteristics are conserved in other BGCs
producing multiple compounds. But what makes this biosynthetic pathway exceptional
is that the bagremycins and p-vinylphenyl-3,4-NHBA, the monomer of ferroverdins, are
not produced under the same culture conditions. Indeed, excess iron supply is man-
datory for p-vinylphenyl-3,4-NHBA production and for its subsequent complexation to
a tripartite molecule, while the bagremycins are produced under conditions of low iron
levels. Thus, iron is a key molecule that determines the distinct biological activities
produced by S. lunaelactis: bagremycins display antibacterial, antifungal, and antipro-
liferative activities, presumably in order to inhibit growth of neighboring competing
bacteria and fungi and/or to control self-proliferation, while p-vinylphenyl-3,4-NHBA
production would be required (to limit iron-mediated oxidative damage) only when
iron excess constitutes a main threat. The change of the amino in a nitroso group in
bagremycin allows complexation with iron, which strongly suggests an evolutionary
driver for this chemical diversification.
We propose a possible biosynthetic pathway for both bagremycins and ferroverdins
(Fig. 8) on the basis of the deduced function of the different components of the bag/fev
clusters and of the current knowledge on the biosynthetic pathway of bagremycins (22,
30, 31, 34). In addition, as biosynthesis is known to occur for two other types of
amino/nitroso-aromatic compounds, namely, grixazones (gri genes) and 4-hydroxy-3-
FIG 7 Iron supply is mandatory for production of p-vinylphenyl-3-nitroso-4-hydroxybenzoate. (A) (Left panel) HPLC chromatogram showing the identification
of p-vinylphenyl-3-nitroso-4-hydroxybenzoate in the extracts of S. lunaelactis MM109 grown on R2YE plus 1 mM FeCl3 (green curve) and the (right panel)
absorbance spectrum from 200 to 800 nm of p-vinylphenyl-3-nitroso-4-hydroxybenzoate. Note the absence of the compound when S. lunaelactis MM109 is
grown on R2YE (black line). (B) Mass spectrum of the compound present in the chromatographic peak and its proposed structure. (C) MS/MS spectra of
p-vinylphenyl-3-nitroso-4-hydroxybenzoate with the proposed fragmentation mechanism.
Martinet et al. ®
July/August 2019 Volume 10 Issue 4 e01230-19 mbio.asm.org 10
 on S
eptem















nitrosobenzamide (nsp genes), the available information regarding these BGCs is useful
to predict steps shared by the studied pathways.
As demonstrated previously, bagremycin A is derived from precursors p-vinylphenol
and 3-amino-4-hydroxybenzoic acid (3,4-AHBA) (22). The p-vinylphenol precursor is
generated in two steps from L-tyrosine, with the first step consisting of deamination by
FevV/BagA in trans-coumaric acid and the second step being decarboxylation in
p-vinylphenol by FevK (BagM) and FevL (BagN). Indeed, FevK and FevL form a UbiX-
UbiD system in which UbiD is a decarboxylase that requires prenylated flavin mono-
nucleotide (FMN) as a cofactor, which is provided by the flavin prenyltransferase UbiX
(35). Regarding the second precursor, 3,4-AHBA, it was demonstrated previously that it
is formed from dihydroxyacetone phosphate (DHAP) and L-aspartic-4-semialdehyde
(ASA) through two reactions catalyzed by BagB (FevI) and BagC (FevH) (30). Conden-
sation of p-vinylphenol and 3,4-AHBA to form bagremycin A would be mediated by
FevW, which shows high levels of similarity to proteins of the phenylacetate-CoA ligase
family, which catalyze the condensation of two molecules by their carboxylic acid and
alcohol moieties through adenylation.
Regarding the synthesis of p-vinylphenyl-3,4-NHBA, the monomer of ferroverdin A
and a major monomer of other ferroverdins, we propose that it would directly result
from precursors p-vinylphenol and 4-hydroxy-3-nitrosobenzoic acid (4,3-HNBA) (Fig. 7).
Direct generation of 4.3-HNBA would occur via the nitrosation of 3,4-AHBA and would
be mediated by the copper-containing oxidase FevF (with FevE as chaperone). FevF is
a copper-containing oxidase which is orthologous to NspF and GriF, while FevE is a
copper chaperone orthologous to NspE and GriE (Table 1). NspE bring two coppers to
NspF, which converts 3-amino-4-hydroxybenzamide to 4-hydroxy-3-nitrosobenzamide
in S. murayamaensis (32, 36). Likewise, GriE donates two coppers to GriF, which converts
o-aminophenol into o-quinone imine in Streptomyces griseus (37). Since these FevF/
FevE orthologous proteins mediate the oxidation of 3.4-AHBA-like substrates to gen-
erate quinone imine moieties which would be consecutively nitrosylated, we suggest
that both of these enzymes are able to mediate the transformation of 3,4-AHBA to
FIG 8 Proposed pathway for biosynthesis of bagremycin and ferroverdin.
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4,3-HNBA. Condensation of 4,3-HNBA with p-vinylphenol by FevW would result in the
formation of p-vinylphenyl-3-nitroso-4-hydroxybenzoate, the monomer of ferroverdins.
Finally, in addition to the role of iron as a vital element for growth (38, 39),
morphogenesis, and metabolite production (12, 39, 40), our work reveals an unprece-
dented complexity of natural product biosynthetic pathways where this element is also
an environmental trigger able to change the pattern of natural compounds produced
by a single BGC. By revealing an exception to the concept that a single BGC should
produce a single type of bioactive molecules, our results also highlight the difficulty of
estimating the metabolic potential of an organism on the basis of genomic information
alone.
MATERIALS AND METHODS
Strains and culture conditions. All strains used in this study are listed in Table 1. Escherichia coli
strains were grown in liquid LB or on solid LB medium agar plates and incubated at 37°C. Media used
for solid Streptomyces cultures were R2YE, SFM, and ISP7 agar plates, which were incubated at 28°C.
When required, the antibiotics thiostreptone, kanamycin, nalidixic acid, and ampicillin were added in the
culture media. The type strain S. lunaelactis MM109T (25) and other S. lunaelactis strains were isolated
from the cave “Grotte des Collemboles’ Collemboles” (Comblain-au-Pont, Belgium) (25–27). The medium
compositions used and the methods associated with Streptomyces species were all as described previ-
ously (41).
Creation of fevR knockout and overexpression mutants in S. lunaelactis MM109. In order to
assess the effect of fevR/bagI on production of both bagremycin and ferroverdin, we first generated a S.
lunaelactis MM109 knockout strain in which orf SLUN21380 was interrupted by a single-crossover event
with insertion of a thiostreptone resistance cassette. A 791-bp internal fragment (starting at position nt
116 and lacking the last 81 nt of SLUN21380) was amplified by PCR using primers fevR118f_XbaI
(TCTCTAGACGAACCAGGTGGTCAGCC) and fevR909r_PstI (CGCTGCAGGTCGTTCTCCAGGCGC) (the un-
derlined characters represent restriction sites). The PCR product was cloned into plasmid pJET1.2 (Blunt
cloning vector; Thermo Fisher Scientific), and the product was named pBDF027 and sequenced for
verification of the amplified PCR fragment. This plasmid was then digested by XbaI and PstI-HF restriction
enzymes (NEB), and the fevR insertion was subsequently cloned into pSET151 (41) digested with the same
enzymes. The plasmid resulting from the ligation, named pBDF028, was introduced into the S. lunaelactis
MM109 chromosome by intergeneric conjugative transfer using methylation-deficient Escherichia coli
ET12567 containing the plasmid pUZ8002 (ETpUZ) as conjugation partner. After growth of E. coli ETpUZ
to an optical density (OD) of 0.4 (50 ml of culture in a mixture of LB plus chloramphenicol [30 g/ml] plus
kanamycin [50 g/ml] plus ampicillin [100 g/ml]), cells were washed to remove antibiotics and mixed
with S. lunaelactis spores for mating. Selection of exconjugants was carried out on soy flour mannitol
(SFM) medium (plus 10 mM MgCl2) overlaid with thiostrepton (50 g/ml) and nalidixic acid (25 g/ml)
after 16 h of incubation at 28°C. The single-crossover insertion of pBDF028 into the fevR locus was
confirmed by PCR, and one selected clone was named fevR (MM109BD1) for further analyses.
To generate a S. lunaelactis strain overproducing FevR, an entire copy of fevR (slun21380) that
included the 217-bp upstream and 360-bp downstream regions was amplified by PCR with primers
BDF53 (GATCTAGAAAGCTTGGCTCTGTCCAGTGAGACATCC) and BDF54 (GCGAATTCGTACTCGATGTCACCC
GCC) to obtain a 1,570-bp fragment flanked by EcoRI and XbaI restriction sites. The PCR product was first
cloned into pJET1.2, and the product was named pBDF019. Using EcoRI-HF and XbaI enzymes, the
1,570-bp fevR-containing fragment was cloned into a pSET152 (41) integrative vector, producing
pBDF021. Conjugation was performed with spores (108) of S. lunaelactis MM109 on SFM (plus 10 mM
MgCl2) overlaid with apramycin and nalidixic acid. Integration of the plasmid was confirmed by PCR with
pSET_forward (GAGCGGATAACAATTTCACACAGGA) and BDF53 or pSET_reverse (CGCCAGGGTTTTCCCA
GTCACGAC) and BDF54 primers. The selected MM109T derivative with pBDF021 inserted to add an
additional copy of slun21380 (fevR) controlled by its native promoter was named MM109BD2 (Table 2).
For complementation of the fevR mutant (strain MM109BD1), an entire copy of fevR was excised
from pBDF019 using EcoRI and XbaI restriction sites and cloned in the same sites of the intermediate-
copy-number pHJL401 plasmid (10 copies) was achieved by conjugation with plasmid pBDF029,
leading to production of pBDF022. To include in pBDF022 the origin of transfer required for conjugation
and a resistance marker for selection of exconjugants, the apramycin resistance cassette (from pIJ773)
containing both oriT (RK2) and aac(3)IV (ApraR) was amplified by PCR with primers Apra_P1 (ATTCCGG
GGATCCGTCGACC) and Apra_P2_HindIII (AAAAAGCTTTGTAGGCTGGAGCTGCTTC) and cloned in the same
sites of pBDF022, resulting in plasmid pBDF029. Conjugation of pBDF29 into spores (108) of S. lunaelactis
MM109BD1 was performed as described above.
Compound extraction and analysis by high-pressure liquid chromatography (HPLC). Com-
pound extraction and HPLC analysis were mainly performed as described previously (26). All S. lunaelactis
strains were cultured for 10 days on different solid media on petri dishes (90-mm diameter, 25 ml of
medium) and incubated at 28°C. The solid cultures were cut into small pieces (about 0.5 by 0.5 cm) and
then mixed overnight with an equal volume (25 ml per plate) of ethyl acetate. The mixture was
centrifuged (20 min at 4,000 rpm) and the supernatant was evaporated (25°C at 210 rpm) on a rotary
evaporator (IKA RV10 digital; VWR, Radnor, PA, USA). The dried crude extract was resuspended in 1 ml of
acetonitrile for further analyses. The full extract was then fractionated by HPLC (Waters, Milford, MA, USA)
using a Waters 2695 Separations Module (Alliance) with a Waters 2998 photodiode array detector
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coupled to a Waters Fraction Collector (model WFC III). The extracts were analyzed on a Luna Omega PS
C18 column (Phenomenex) (2.1 mm by 150 mm, 5-m particle size, 100-Å pore size) at a column
temperature of 40°C. Extract separation was achieved by increasing the ratio of acetonitrile (Barker; HPLC
Far UV grade) to water (MilliQ filtration using a pore size of 0.22 m)– 0.05% trifluoroacetic acid (TFA)
(Thermo Fisher Scientific, San Jose, CA, USA; sequencing grade) (from 0% to 100% acetonitrile during
80 min) at a flow rate of 450 l/min. Online UV absorption measurement was performed from 190 to
800 nm. Data were analyzed using Empower 3 software (Waters, Milford, MA, USA) and Xcalibur v2.2
software (Thermo Fisher Scientific, San Jose, CA, USA). Fractions were subsequently tested for antibac-
terial activities against Staphylococcus aureus (ATCC 25923) by disk diffusion assay as described previ-
ously (26).
Compound identification by ultraperformance liquid chromatography-tandem mass spectrom-
etry (UPLC-MS/MS). UV light-visible light absorbance spectra were obtained by analytical HPLC RP-C18
analyses. High-resolution electrospray ionization mass spectrometry (HRESIMS) data were acquired on a
Q Exactive Plus hybrid Quadrupole-Orbitrap mass spectrometer (Thermo Fisher Scientific, San Jose, CA,
USA). Briefly, compounds were separated by reverse-phase chromatography using ultraperformance
liquid chromatography (UPLC I-Class; Waters) and a Nucleodur C18ec column (Macherey-Nagel) (2.0 mm
by 150 mm, 5-m particle size). Elution was achieved by increasing the ratio of acetonitrile to water
(MilliQ filtration using a pore size of 0.22 m)– 0.05% trifluoroacetic acid (for positive-ionization mode)
(from 0% to 62.5% during 30 min and then from 62.5% to 100% during 8 min) at a flow rate of
300 l/min. For the negative-ionization mode, elution was achieved by increasing the ratio of acetonitrile
to water (MilliQ filtration using a pore size of 0.22 m)– 0.1% formic acid (from 0% to 62.5% during 30 min
and then from 62.5% to 100% during 8 min) at a flow rate of 300 l/min on a Luna Omega PS C18 column
(Phenomenex) (2.1 mm by 150 mm, 5-m particle size, 100-Å pore size). On-line UV absorption mea-
surement was performed at 210 and 265 nm, and the chromatography system was finally coupled to a
Q Exactive Plus hybrid Quadrupole-Orbitrap mass spectrometer (Thermo Fisher Scientific, San Jose, CA,
USA), operated in positive-ion mode (for bagremycins) and in negative mode (for ferroverdins and
bagremycins), and programmed for data-dependent acquisitions. Survey scans were acquired at a
mass-resolving power level of 140,000 FWHM (full width at half-maximum) and at 100 to 1,500 m/z
(accumulation target, 1  106 ion). The five ions showing the greatest intensity were then selected for
tandem mass spectrometry (MS/MS) experiments by the use of higher-energy collision dissociation (HCD)
fragmentations and stepped normalized collision energy (NCE) (21,2; 25; 28) within 2-atomic-mass-unit
(amu) isolation windows (resolution, 17,500; accumulation target, 1  105 ions). Dynamic exclusion was
enabled for 10 s. Data were analyzed using Xcalibur v2.2 (Thermo Fisher Scientific, San Jose, CA, USA).
Each of the compounds was identified in accordance with its exact mass and isotope pattern,
observation of the MS/MS spectra obtained by molecular ion fragmentation, and the UV-VIS absorbance
spectra. For each molecule, a fragmentation pathway was proposed (see Fig. S3 in the supplemental
material).
Bioinformatics. The complete genome sequence of the S. lunaelactis MM109T type strain was
assembled from Illumina HiSeq and MiSeq short reads (Illumina, CA, USA) and Nanopore MinION long
reads (Oxford Nanopore Technologies, United Kingdom) as described previously (28). Other S. lunaelactis
strains genomes were assembled from Illumina reads only, using the complete genome sequence of the
S. lunaelactis MM109T type strain as the template (29).
The sequencing was performed at the GIGA-Research Center (Liège University, Belgium) (HiSeq and
MinION) and at the Luxembourg Institute of Science and Technology (Belvaux, Luxembourg) (MiSeq).
Phylogeny analyses were performed with sequences of homolog proteins from the fev (S. lunaelactis
MM109, Streptomyces sp. WK-5344), bag (Streptomyces sp. Tü 4128), gri (S. griseus), and nsp (S. muray-
amaensis) clusters. Proteins were aligned with MAFFT (v7.273, localpair mode), and alignments were
trimmed and internal gaps removed. Phylogenetic inference was deduced using the maximum likelihood
method as implemented in RAxML (v8.1.17, rapid bootstrapping mode with 1,000 replicates, GAMMA
model of rate heterogeneity with WAG amino acid substitution matrix).
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/mBio
.01230-19.
FIG S1, TIF file, 1.6 MB.
FIG S2, TIF file, 0.2 MB.
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